JP2006506071A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506071A5
JP2006506071A5 JP2004552160A JP2004552160A JP2006506071A5 JP 2006506071 A5 JP2006506071 A5 JP 2006506071A5 JP 2004552160 A JP2004552160 A JP 2004552160A JP 2004552160 A JP2004552160 A JP 2004552160A JP 2006506071 A5 JP2006506071 A5 JP 2006506071A5
Authority
JP
Japan
Prior art keywords
cancer
pipa
tumor
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004552160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506071A (ja
JP4757493B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/036134 external-priority patent/WO2004043239A2/en
Publication of JP2006506071A publication Critical patent/JP2006506071A/ja
Publication of JP2006506071A5 publication Critical patent/JP2006506071A5/ja
Application granted granted Critical
Publication of JP4757493B2 publication Critical patent/JP4757493B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004552160A 2002-11-13 2003-11-13 抗原ｐｉｐａおよびそれに結合する抗体 Expired - Fee Related JP4757493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42619202P 2002-11-13 2002-11-13
US60/426,192 2002-11-13
PCT/US2003/036134 WO2004043239A2 (en) 2002-11-13 2003-11-13 Antigen pipa and antibodies that bind thereto

Publications (3)

Publication Number Publication Date
JP2006506071A JP2006506071A (ja) 2006-02-23
JP2006506071A5 true JP2006506071A5 (enExample) 2007-01-11
JP4757493B2 JP4757493B2 (ja) 2011-08-24

Family

ID=32313118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004552160A Expired - Fee Related JP4757493B2 (ja) 2002-11-13 2003-11-13 抗原ｐｉｐａおよびそれに結合する抗体

Country Status (6)

Country Link
US (1) US7405061B2 (enExample)
EP (1) EP1581096A4 (enExample)
JP (1) JP4757493B2 (enExample)
AU (1) AU2003295474B2 (enExample)
CA (1) CA2505633A1 (enExample)
WO (1) WO2004043239A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574623B2 (en) 2004-12-22 2013-11-05 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US8652526B2 (en) 2004-12-22 2014-02-18 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US8686052B2 (en) 2007-03-30 2014-04-01 Nitto Denko Corporation Targeting agent for cancer cell or cancer-associated fibroblast

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505633A1 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto
AU2006210589B2 (en) 2005-02-02 2011-12-08 Macrogenics West, Inc. ADAM-9 modulators
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
EP2714079B2 (en) 2011-05-21 2019-08-28 MacroGenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
EP2724729B1 (en) 2011-06-21 2018-12-26 Nitto Denko Corporation Apoptosis-inducing agent
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5496550A (en) 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
ATE207535T1 (de) 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
WO1994015969A1 (fr) 1993-01-14 1994-07-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticorps anti-vih recombine et sa preparation
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997035016A1 (en) 1996-03-18 1997-09-25 Novo Nordisk Biotech Inc Polypeptides having phytase activity and nucleic acids encoding same
CA2249998A1 (en) * 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
WO1998017785A1 (en) 1996-10-18 1998-04-30 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same
DE29803477U1 (de) * 1998-03-03 1998-07-09 P.E.R. Flucht- und Rettungsleitsysteme GmbH, 22885 Barsbüttel Vorrichtung zur Ausbildung aktiv leuchtender Leuchtwegesysteme
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2505633A1 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574623B2 (en) 2004-12-22 2013-11-05 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US8652526B2 (en) 2004-12-22 2014-02-18 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US8686052B2 (en) 2007-03-30 2014-04-01 Nitto Denko Corporation Targeting agent for cancer cell or cancer-associated fibroblast

Similar Documents

Publication Publication Date Title
JP5601836B2 (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
JP5372973B2 (ja) 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
JP4757493B2 (ja) 抗原ｐｉｐａおよびそれに結合する抗体
CN101142236B (zh) Adam-9调节剂
JP5328156B2 (ja) オンコスタチンｍレセプターに対する抗体
JP4621674B2 (ja) Ｋｉｄ３およびｋｉｄ３に結合するｋｉｄ３抗体
US20110045006A1 (en) LUCA2 and Antibodies That Bind Thereto
US20100150921A1 (en) KID31 And Antibodies That Bind Thereto
JP2006506071A5 (enExample)
US20060171952A1 (en) JAM-3 and antibodies that bind thereto
HK1107402B (en) Kid31 and antibodies that bind thereto